Prepregnancy Care and Counseling: A Review.
Clinical review identifies cannabis cessation as a recommended intervention for prepregnancy care to optimize maternal and infant outcomes.
This authoritative clinical review establishes cannabis cessation as a standard component of evidence-based prepregnancy counseling. The inclusion of cannabis alongside tobacco, alcohol, and opioids reflects evolving clinical consensus about periconceptional substance use recommendations.
With two-thirds of reproductive-aged women having modifiable pregnancy risk factors, standardized prepregnancy counseling becomes critical. This JAMA review provides clinical framework for discussing cannabis cessation as part of comprehensive preconception care.
| Study Type | Clinical Review |
| Population | Reproductive-aged women in the United States, with 66.4% having at least one modifiable risk factor |
| Intervention | Prepregnancy care and counseling including substance cessation recommendations |
| Comparator | Not applicable for review study |
| Primary Outcome | Maternal and infant health outcomes optimization |
| Key Finding | Cannabis cessation listed among recommended interventions alongside tobacco, alcohol, and opioid cessation |
| Journal | JAMA |
| Year | 2024 |
Cannabis cessation should be recommended as part of standard prepregnancy counseling for all individuals planning conception. This recommendation appears in authoritative clinical guidance alongside other established substance cessation interventions.
The review does not provide specific data on cannabis-related pregnancy risks or cessation intervention effectiveness. The abstract does not detail the evidence quality supporting the cannabis cessation recommendation or specify timing for cessation.
The abstract provides no mechanistic rationale or risk quantification for the cannabis recommendation. Without seeing the full methodology, it’s unclear how this recommendation was prioritized relative to other interventions or what evidence threshold was applied.
Cannabis cessation has entered mainstream prepregnancy care recommendations in authoritative clinical literature. However, the specific evidence supporting this recommendation and practical implementation guidance require review of the full clinical literature beyond this abstract.
Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
Why is cannabis cessation recommended before pregnancy?
Cannabis cessation is identified as a key recommended intervention for prepregnancy care to optimize maternal and infant outcomes. While this review doesn’t provide specific cannabis-related risk data, cannabis is grouped with other substances like tobacco, alcohol, and opioids that should be discontinued before conception to reduce pregnancy complications.
How far in advance should I stop using cannabis before trying to conceive?
The review emphasizes that prepregnancy care should begin before conception to optimize maternal health, but doesn’t specify exact timing for cannabis cessation. Given that 66.4% of reproductive-aged women have modifiable risk factors, early intervention and cessation as part of comprehensive prepregnancy planning is recommended.
What other substances should be avoided along with cannabis when planning pregnancy?
The review recommends cessation of tobacco, alcohol, cannabis, and opioids as part of prepregnancy care. Tobacco smoking specifically increases risks of stillbirth, neonatal death, and perinatal death, highlighting the importance of substance cessation for optimal pregnancy outcomes.
What are the essential components of prepregnancy care beyond cannabis cessation?
Key interventions include folic acid supplementation (which reduces neural tube defects with RR 0.67), immunizations against hepatitis B, varicella, and rubella, and screening for syphilis and HIV. Folic acid supplementation before pregnancy is particularly important as it’s associated with a 33% reduction in fetal neural tube defects.
How common are modifiable risk factors among women of reproductive age?
According to this review, 66.4% of reproductive-aged women in the US have at least one modifiable risk factor for adverse pregnancy outcomes. This highlights the significant opportunity for prepregnancy interventions, including cannabis cessation, to improve maternal and infant health outcomes.
